Temsirolimus
- Generic Name
- Temsirolimus
- Brand Names
- Torisel
- Drug Type
- Small Molecule
- Chemical Formula
- C56H87NO16
- CAS Number
- 162635-04-3
- Unique Ingredient Identifier
- 624KN6GM2T
- Background
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
- Indication
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
- Associated Conditions
- Advanced Renal Cell Carcinoma
- Associated Therapies
- -
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00693433
- Locations
- 🇺🇸
Veteran's Administration Medical Center, Las Angeles, California, United States
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 72
- Registration Number
- NCT00678769
- Locations
- 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- London Health Sciences Centre
- Target Recruit Count
- 28
- Registration Number
- NCT00659568
- Locations
- 🇨🇦
London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 791
- Registration Number
- NCT00631371
- Locations
- 🇭🇺
Uzsoki Utcai Korhaz, Budapest, Hungary
🇨🇱Fundacion Arturo Lopez Perez, Santiago, Chile
🇭🇰Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong
Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 160
- Registration Number
- NCT00619268
- Locations
- 🇫🇷
Centre Jean Perrin, Clermont Ferrand, France
🇫🇷Centre Hospitalier Universitaire de Bordeaux - Hôpital St André, Bordeaux, France
🇫🇷Centre Hospitalier Universiariare Lyon, Hôpital Lyon Sud, Lyon, France
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
- Conditions
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 193
- Registration Number
- NCT00610493
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
- Conditions
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT00600496
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Jeffrey W. Clark, MD
- Target Recruit Count
- 35
- Registration Number
- NCT00593060
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer
- Conditions
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT00593008
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
- First Posted Date
- 2007-08-08
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00512668
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.